Why is Mankind Pharma falling/rising?

As of 10-Nov, Mankind Pharma Ltd is experiencing a decline in its stock price, currently at 2,234.40, which reflects a decrease of 28.9 points or 1.28%. The stock has been underperforming, having fallen consecutively for the last four days, resulting in a total decline of 6.97% over the past week. Additionally, Mankind Pharma is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. Despite a low debt-to-equity ratio of 0.03 and high institutional holdings at 24.76%, the company has reported flat results, with a significant drop in profits of 20.05% over the last six months and a negative return of 15.94% over the past year, which has contributed to the stock's recent downturn.
In the broader market context, Mankind Pharma's performance has significantly lagged behind the benchmark, with a 1-week return of -6.97% compared to the Sensex's -0.53%. This underperformance is further highlighted by the stock's year-to-date decline of 22.33%, while the Sensex has gained 6.91% during the same period. The stock's inability to generate positive returns in both the short and long term, coupled with its expensive valuation relative to peers, has likely led to a lack of investor confidence, contributing to its current price decline.